A review of 10 articles finds that nearly 9% of adverse event (AE) reports with biologics used to treat psoriasis were gastrointestinal (GI)-related and suggests that the relative rate may be higher ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Patients with psoriasis who were treated with phototherapy and biologics had a lower incidence of PsA than those treated with phototherapy alone.

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

A new study published in the Journal of American Medical Association showed that psoriasis patients who used antibiotics had ...

Please provide your email address to receive an email when new articles are posted on . There was no significant difference in cardiovascular risks among patients treated with biologics for psoriatic ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Some 25% of patients with psoriasis eventually develop psoriatic arthritis, but the risk may be mitigated with targeted therapies. This single-center study found that progression to PsA was more ...

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Objectives: (1) To develop a clinically useful model with which dermatologists can understand the potential uses of biologic therapy for psoriasis and understand the potential differences among these ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...